Get the Stockscreener App
3.02
1.00%
0.03
After Hours:
3.02
Genelux Corp stock is traded at $3.02, with a volume of 187.78K.
It is up +1.00% in the last 24 hours and up +3.07% over the past month.
Genelux Corp is a late-stage biopharmaceutical firm focused on developing oncolytic viral immunotherapies for cancer. Its pipeline includes clinical and preclinical candidates designed to target tumor cells and stimulate an immune response against tumor-specific antigens. The company is focused on the development of next-generation oncolytic viral immunotherapies that are designed to generate a personalized multi-prong attack to overwhelm a tumor's sophisticated defense mechanisms.
See More
Previous Close:
$2.99
Open:
$3.02
24h Volume:
187.78K
Relative Volume:
0.99
Market Cap:
$135.42M
Revenue:
$8,000
Net Income/Loss:
$-33.58M
P/E Ratio:
-3.5375
EPS:
-0.8537
Net Cash Flow:
$-27.88M
1W Performance:
+4.14%
1M Performance:
+3.07%
6M Performance:
-10.91%
1Y Performance:
+1.34%
1-Day Range:
$2.955
$3.18
1-Week Range:
$2.83
$3.18
52-Week Range:
$2.29
$8.535
Genelux Corp Stock (GNLX) Company Profile
Name
Genelux Corp
Sector
Industry
Phone
805-267-9889
Address
2625 TOWNSGATE ROAD, SUITE 230, WESTLAKE VILLAGE
Compare GNLX vs VRTX, REGN, ARGX, ALNY, RVMD
| Stocks | Price | Market Cap | Revenue | Net Income | Cash Flow | EPS |
|---|---|---|---|---|---|---|
GNLX
Genelux Corp
|
3.02 | 134.97M | 8,000 | -33.58M | -27.88M | -0.8537 |
VRTX
Vertex Pharmaceuticals Inc
|
529.59 | 126.07B | 12.34B | 4.34B | 3.71B | 16.87 |
REGN
Regeneron Pharmaceuticals Inc
|
649.81 | 65.37B | 14.92B | 4.42B | 3.79B | 41.04 |
ARGX
Argen X Se Adr
|
916.80 | 57.70B | 4.16B | 1.29B | 734.26M | 19.58 |
ALNY
Alnylam Pharmaceuticals Inc
|
313.04 | 40.19B | 4.29B | 577.22M | 641.34M | 4.2086 |
RVMD
Revolution Medicines Inc
|
189.99 | 39.82B | 742.00K | -1.37B | -1.07B | -7.0731 |
Genelux Corp Stock (GNLX) Upgrades & Downgrades
| Date | Action | Analyst | Rating Change |
|---|---|---|---|
| Oct-21-25 | Initiated | Lake Street | Buy |
| Oct-29-24 | Initiated | Guggenheim | Buy |
| Aug-28-24 | Initiated | ROTH MKM | Buy |
| Nov-27-23 | Initiated | H.C. Wainwright | Buy |
| Sep-12-23 | Initiated | Maxim Group | Buy |
| Feb-15-23 | Initiated | The Benchmark Company | Speculative Buy |
View All
Genelux Corp Stock (GNLX) Latest News
[144] GENELUX Corp SEC Filing - Stock Titan
Genelux Announces Publication of Translational Analysis Supporting Immune Activation and Chemotherapy Sensitization with Olvi‑Vec in Ovarian Cancer - The Manila Times
Genelux says Olvi-Vec may reawaken platinum response in ovarian cancer - Stock Titan
Genelux Corp. Actuals & Estimates (NASDAQ:GNLX) - TradingView
Genelux Corp (GNLX) Risk Assessment: Volatility, Financial Risk & Investment Risk - TradingKey
Genelux Corp (GNLX) Earnings Forecast: Future EPS & Revenue Growth Estimates - TradingKey
Genelux Corporation 8-K Filing: Company Details, Nasdaq Listing, and Emerging Growth Status (June 2026) - Minichart
Genelux elects director and ratifies auditor at annual shareholder meeting - Investing.com
Genelux elects director and ratifies auditor at annual shareholder meeting By Investing.com - Investing.com Nigeria
Form 8K Genelux Corp For: 22 June By Investing.com - Investing.com South Africa
Genelux (GNLX) 2026 meeting backs director John Smither and auditor - Stock Titan
Genelux (GNLX) director receives RSU and stock option grants - Stock Titan
Genelux (GNLX) director receives RSUs and stock options in new grant - Stock Titan
GENELUX (GNLX) CFO receives 278,906 restricted stock units as equity grant - Stock Titan
Genelux (NASDAQ: GNLX) grants 233,957 RSUs to General Counsel Eric Groen - Stock Titan
GENELUX (GNLX) CTO granted 174,841 RSUs under 2022 equity plan - Stock Titan
GENELUX (NASDAQ: GNLX) director James L. Tyree receives RSU and option grants - Stock Titan
Genelux (NASDAQ: GNLX) grants CEO 730,601 RSUs under 2022 plan - Stock Titan
GENELUX (GNLX) Chief Scientific Officer awarded 119,318 RSUs in equity grant - Stock Titan
GENELUX (NASDAQ: GNLX) director granted RSUs and options in new equity awards - Stock Titan
Genelux Corp (GNLX) Technical Analysis: Support, Resistance, Indicators & Moving Averages - TradingKey
Genelux Corp (GNLX) Institutional Confidence - TradingKey
Genelux Corp (GNLX) Dividends & Stock Splits: Historical Payouts and Event Timeline - TradingKey
Genelux Corp (GNLX) Shareholder Structure: Major Shareholders & Institutional Holdings - TradingKey
Genelux Corp (GNLX) Revenue Breakdown: Business Segments, Regional Revenue & Profit Contribution - TradingKey
Genelux Corp (GNLX) Financial Health: Profitability & Balance Sheet Analysis - TradingKey
Genelux Corp (GNLX) Valuation: PE, PB & Fair Value Analysis - TradingKey
Genelux head of regulatory Ralph Smalling sells $562 in stock By Investing.com - Investing.com India
Tax-related share sale by Genelux (GNLX) Head of Regulatory - Stock Titan
Genelux head of regulatory Ralph Smalling sells $562 in stock - Investing.com
Genelux director Thomas John sold $29,801 in company stock By Investing.com - Investing.com India
Insider Sell: John Thomas Sells 10,000 Shares of Genelux Corp (G - GuruFocus
Genelux director Thomas John sold $29,801 in company stock - Investing.com
GENELUX (NASDAQ: GNLX) director sells 10,000 shares in Rule 10b5-1 trade - Stock Titan
Genelux Corp. Financial Disclosures & SEC Filings - TradingView
GNLX (NASDAQ) director sells 10,000 shares via 10b5-1, $28,957 proceeds - Stock Titan
GNLX Q1 2026 Earnings: EPS Miss Amid Pre-Revenue Development Stage; Stock Edges HigherAnnual Earnings Summary - newsline.com
GNLX Q1 2026 Earnings: EPS Misses Estimates as Company Reports No RevenueEarnings Surprise Stocks - newsline.com
GNLX SEC FilingsGenelux Corp 10-K, 10-Q, 8-K Forms - Stock Titan
GNLX Technical Analysis | Trend, Signals & Chart Patterns | GENELUX CORP (NASDAQ:GNLX) - ChartMill
Genelux president and CEO Zindrick Thomas sells $8,225 in stock By Investing.com - Investing.com Nigeria
Genelux CSO Yu Yong sells $1,798 of common stock - Investing.com UK
Genelux CSO Yu Yong sells $1,798 of common stock By Investing.com - Investing.com Nigeria
Genelux CTO Joseph Cappello sells $1,799 in company stock By Investing.com - Investing.com South Africa
Genelux Corp Stock (GNLX) Financials Data
Revenue
Net Income
Cash Flow
EPS
0.05%
0.74%
Open in Yahoo
|
Open in Google
|
Open in Finviz
|
Open in MarketWatch
|
Open in EDGAR
|
Open in Reuters
Cap:
|
Volume (24h):